We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+9.7%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.59B
AUM Growth
+$300M
Cap. Flow
+$374M
Cap. Flow %
23.51%
Top 10 Hldgs %
49.78%
Holding
111
New
24
Increased
22
Reduced
23
Closed
30

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$67.1M
2
NVCR icon
NovoCure
NVCR
+$58M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$38.1M
4
AZN icon
AstraZeneca
AZN
+$28.6M
5
IART icon
Integra LifeSciences
IART
+$27.9M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$35.3M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$33.2M
3
RVMD icon
Revolution Medicines
RVMD
+$25.4M
4
TXG icon
10x Genomics
TXG
+$21.5M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 83.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYO icon
51
Myomo
MYO
$50.6M
$5.8M 0.36%
+900,000
New +$4.38M
ANAB icon
52
AnaptysBio
ANAB
$1.62B
$5.48M 0.34%
+414,000
New +$10M
ERAS icon
53
Erasca
ERAS
$6.34B
$5.43M 0.34%
2,162,162
– –
EWTX icon
54
Edgewise Therapeutics
EWTX
$4.78B
$4.89M 0.31%
+183,300
New +$5.84M
VCEL icon
55
Vericel Corp
VCEL
$2.29B
$4.43M 0.28%
+80,696
New +$4.08M
CRNX icon
56
Crinetics Pharmaceuticals
CRNX
$8.9B
$4.35M 0.27%
+85,000
New +$4.76M
EPIX
57
DELISTED
ESSA Pharma
EPIX
$4.05M 0.25%
2,262,026
-2,026,141
-47% -$6.45M
NSPR icon
58
InspireMD
NSPR
$33.8M
$3.62M 0.23%
1,378,128
– –
RCKT icon
59
Rocket Pharmaceuticals
RCKT
$387M
$3.41M 0.21%
+271,659
New +$4.09M
MDGL icon
60
Madrigal Pharmaceuticals
MDGL
$11.8B
$3.36M 0.21%
+10,900
New +$3.07M
REPL icon
61
Replimune Group
REPL
$1.08B
$3.18M 0.2%
+262,500
New +$3.19M
APGE icon
62
Apogee Therapeutics
APGE
$10.2B
$3.17M 0.2%
+70,000
New +$3.57M
CALC icon
63
CalciMedica
CALC
$11.2M
$2.78M 0.17%
783,904
– –
MREO
64
Mereo BioPharma
MREO
$48.8M
$2.75M 0.17%
786,953
-60,000
-7% -$236K
YMAB
65
DELISTED
Y-mAbs Therapeutics
YMAB
$2.74M 0.17%
349,982
-50,000
-13% -$609K
ESTA icon
66
Establishment Labs
ESTA
$2.33B
$2.74M 0.17%
59,400
– –
BLCO icon
67
Bausch + Lomb
BLCO
$5.84B
$2.18M 0.14%
120,500
-191,500
-61% -$3.74M
MDXH icon
68
MDxHealth
MDXH
$22.5M
$2.02M 0.13%
851,688
-253,312
-23% -$517K
ELVN icon
69
Enliven Therapeutics
ELVN
$4.31B
$1.7M 0.11%
75,405
-164,300
-69% -$4.26M
REGN icon
70
Regeneron Pharmaceuticals
REGN
$79.5B
$1.64M 0.1%
+2,300
New +$1.93M
TECX
71
Tectonic Therapeutic
TECX
$570M
$1.47M 0.09%
+31,841
New +$1.35M
ADVM
72
DELISTED
Adverum Biotechnologies
ADVM
$1.34M 0.08%
287,246
– –
WHWK
73
Whitehawk Therapeutics
WHWK
$232M
$1.05M 0.07%
333,227
– –
ABVX
74
Abivax
ABVX
$11.3B
$915K 0.06%
125,000
– –
VRDN icon
75
Viridian Therapeutics
VRDN
$2.49B
$872K 0.05%
45,500
-49,500
-52% -$1.08M
1 2
3
4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Soleus Capital Management held 111 positions worth $1.59B, up 23% from $1.29B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Soleus Capital Management deployed $374M of net new capital in Q4 2024, opening 24 new positions and adding to 22 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 1,001,400 shares worth $65.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 93% a quarter earlier.

On the sell side, the largest reduction was Revolution Medicines, an estimated $25.4M trimmed.

  • Soleus Capital Management's largest Q4 2024 buy was BioMarin Pharmaceuticals: 1,001,400 shares worth $65.8M.
  • Soleus Capital Management added most to Krystal Biotech in Q4 2024, an estimated $25.1M increase.
  • Soleus Capital Management's biggest Q4 2024 reduction was Revolution Medicines, cutting an estimated $25.4M.
  • Soleus Capital Management fully exited Sanofi in Q4 2024, selling an estimated $35.3M.
  • Soleus Capital Management's ten largest holdings make up 50% of its $1.59B portfolio in Q4 2024.
  • Soleus Capital Management opened 24 new positions and closed 30 in Q4 2024.
  • Soleus Capital Management's portfolio value rose 23% quarter-over-quarter to $1.59B.

Based on Soleus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.